Evolocumab (Repatha)-A Second PCSK9 Inhibitor to Lower LDL-Cholesterol (Reprinted from The Medical Letter on Drugs and Therapeutics, vol 57, pg 140, 2015)

被引：8
作者：
不详
机构：
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2015年 / 314卷 / 21期
关键词：
DOUBLE-BLIND; HYPERCHOLESTEROLEMIA; EFFICACY; SAFETY; TRIAL;
D O I：
10.1001/jama.2015.14772
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2298 / 2299
页数：2
相关论文
共 8 条
  • [1] [Anonymous], 2015, MED LETT DRUGS THER, V57, P113
  • [2] [Anonymous], MED LETT DRUGS THER
  • [3] A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
    Blom, Dirk J.
    Hala, Tomas
    Bolognese, Michael
    Lillestol, Michael J.
    Toth, Phillip D.
    Burgess, Lesley
    Ceska, Richard
    Roth, Eli
    Koren, Michael J.
    Ballantyne, Christie M.
    Monsalvo, Maria Laura
    Tsirtsonis, Kate
    Kim, Jae B.
    Scott, Rob
    Wasserman, Scott M.
    Stein, Evan A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (19) : 1809 - 1819
  • [4] Anti-PCSK9 Monotherapy for Hypercholesterolemia The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab
    Koren, Michael J.
    Lundqvist, Pernille
    Bolognese, Michael
    Neutel, Joel M.
    Monsalvo, Maria Laura
    Yang, Jingyuan
    Kim, Jae B.
    Scott, Rob
    Wasserman, Scott M.
    Bays, Harold
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (23) : 2531 - 2540
  • [5] PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
    Raal, Frederick J.
    Stein, Evan A.
    Dufour, Robert
    Turner, Traci
    Civeira, Fernando
    Burgess, Lesley
    Langslet, Gisle
    Scott, Russell
    Olsson, Anders G.
    Sullivan, David
    Hovingh, G. Kees
    Cariou, Bertrand
    Gouni-Berthold, Ioanna
    Somaratne, Ransi
    Bridges, Ian
    Scott, Rob
    Wasserman, Scott M.
    Gaudet, Daniel
    [J]. LANCET, 2015, 385 (9965) : 331 - 340
  • [6] Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
    Raal, Frederick J.
    Honarpour, Narimon
    Blom, Dirk J.
    Hovingh, G. Kees
    Xu, Feng
    Scott, Rob
    Wasserman, Scott M.
    Stein, Evan A.
    Investigators, T. E. S. L. A.
    [J]. LANCET, 2015, 385 (9965) : 341 - 350
  • [7] Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
    Sabatine, Marc S.
    Giugliano, Robert P.
    Wiviott, Stephen D.
    Raal, Frederick J.
    Blom, Dirk J.
    Robinson, Jennifer
    Ballantyne, Christie M.
    Somaratne, Ransi
    Legg, Jason
    Wasserman, Scott M.
    Scott, Robert
    Koren, Michael J.
    Stein, Evan A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (16) : 1500 - 1509
  • [8] Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
    Zhang, Xin-Lin
    Zhu, Qing-Qing
    Zhu, Li
    Chen, Jian-Zhou
    Chen, Qin-Hua
    Li, Guan-Nan
    Xie, Jun
    Kang, Li-Na
    Xu, Biao
    [J]. BMC MEDICINE, 2015, 13
1